This trial tests if a study drug (JSP191) can improve success of stem cell transplants for people 4-65 w/ Chronic Granulomatous Disease.
- Chronic Granulomatous Disease
1 Primary · 3 Secondary · Reporting Duration: Day 100 and 2 years post transplant
Awards & Highlights
1 Treatment Group
Single arm study
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Single arm study · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 4 - 65 · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there still capacity in this research project for new participants?
"Unfortunately, this clinical trial is no longer in the process of recruiting patients. Initially posted on December 6th 2022 and last updated November 30th 2022, it has since ceased to look for new participants; however, there are 21 other trials that remain receptive to new enrollees." - Anonymous Online Contributor
Is this research endeavor accepting volunteers who are 50 years or older?
"The eligibility criteria for this medical experiment necessitates that participants are between 4 and 65 years of age. Simultaneously, there are 15 studies open to minors and 13 trials accessible for individuals over the age of 65." - Anonymous Online Contributor
Is it possible for me to join this research endeavor?
"This clinical trial is seeking to enrol 30 individuals aged 4-65 years who are diagnosed with Chronic Granulomatous Disease (CGD). To be admitted, participants must meet the following conditions: demonstrate CGD symptoms and complications; have an unrelated donor ready for transplantation or a Quartile 1/2 oxidase production level; reside within one hour of NIH upon post-transplant period commencement; appoint a responsible adult relative as Durable Power of Attorney for Health Care Decision Making through form NIH 200. Additionally, female patients require contraceptive methods such as oral pills, patches, Norplant implants, Depo-Provera injections etc" - Anonymous Online Contributor